Home > New hope for epidermolysis bullosa patients

New hope for epidermolysis bullosa patients

Presented By
Prof. Dedee F. Murrell, St George Hospital, University of New South Wales, Australia
EADV 2020
A multinational, phase 3 study with Oleogel-S10 for epidermolysis bullosa was the first to reach its primary endpoint. Complete wound closure was reached by 41.3% of wounds treated with Oleogel-S10 versus 28.9% of those treated with a control gel. A specific treatment for epidermolysis bullosa (EB) has been lacking as the standard of care until now comprised non-adhesive bandages and topical treatments (i.e. anti-microbials, corticosteroids). The agent that is expected to change this is derived from the bark of the birch t...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on